{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:47:28Z","timestamp":1794854848466,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K01AG071843"],"award-info":[{"award-number":["K01AG071843"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Center for AIDS Research, Emory University","doi-asserted-by":"publisher","award":["P30 AI050409"],"award-info":[{"award-number":["P30 AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH121424"],"award-info":[{"award-number":["R01 MH121424"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH121424"],"award-info":[{"award-number":["R01 MH121424"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Washington \/ Fred Hutch Center for AIDS Research","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}]},{"name":"University of Washington \/ Fred Hutch Center for AIDS Research","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}]},{"name":"University of Washington Behavioral Research Center for HIV","award":["P30 MH123248"],"award-info":[{"award-number":["P30 MH123248"]}]},{"name":"University of Washington Behavioral Research Center for HIV","award":["P30 MH123248"],"award-info":[{"award-number":["P30 MH123248"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10546-w","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:32:16Z","timestamp":1739957536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment"],"prefix":"10.1186","volume":"25","author":[{"given":"Enrique M.","family":"Saldarriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Barthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Brah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"10546_CR1","unstructured":"Centers for Disease Control and Prevention (CDC). HV surveillance supplemental report: estimated HIV incidence and prevalence in the United States, 2018\u20132022. 2024."},{"key":"10546_CR2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321:844\u20135.","journal-title":"JAMA"},{"key":"10546_CR3","doi-asserted-by":"crossref","unstructured":"Crim SM. Barriers to antiretroviral therapy adherence among HIV-positive hispanic and latino men who have sex with men \u2014United States, 2015\u20132019. MMWR Morb Mortal Wkly Rep. 2020;69.","DOI":"10.15585\/mmwr.mm6940a1"},{"key":"10546_CR4","doi-asserted-by":"crossref","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13:e1002183.","journal-title":"PLoS Med"},{"key":"10546_CR5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11908-008-0083-y","volume":"10","author":"JM Simoni","year":"2008","unstructured":"Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10:515\u201321.","journal-title":"Curr Infect Dis Rep"},{"key":"10546_CR6","unstructured":"Centers for Disease Control and Prevention (CDC). HV surveillance supplemental report: monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 territories and freely associated states, 2022. 2024."},{"key":"10546_CR7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17:1227\u201338.","journal-title":"Expert Opin Drug Deliv"},{"key":"10546_CR8","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","volume":"8","author":"H Jaeger","year":"2021","unstructured":"Jaeger H, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8:e679\u201389.","journal-title":"Lancet HIV"},{"key":"10546_CR9","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton ET, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet Lond Engl. 2021;396:1994\u20132005.","journal-title":"Lancet Lond Engl"},{"key":"10546_CR10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet Lond Engl. 2017;390:1499\u2013510.","journal-title":"Lancet Lond Engl"},{"key":"10546_CR11","doi-asserted-by":"crossref","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase II study of cabotegravir\u2009+\u2009rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13:e0190487.","journal-title":"PLoS ONE"},{"key":"10546_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33393\/dti.2021.2342","volume":"15","author":"S Losi","year":"2021","unstructured":"Losi S, et al. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13\u201320.","journal-title":"Drug Target Insights"},{"key":"10546_CR13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, De Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. PharmacoEconomics. 2014;32:883\u2013902.","journal-title":"PharmacoEconomics"},{"key":"10546_CR14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices For Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"10546_CR15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, et al. Conjoint analysis applications in health - how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3:249\u201356.","journal-title":"Patient"},{"key":"10546_CR16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2016;19:300\u201315.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"10546_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12981-022-00435-6","volume":"19","author":"AT Brah","year":"2022","unstructured":"Brah AT, et al. The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. AIDS Res Ther. 2022;19:13.","journal-title":"AIDS Res Ther"},{"key":"10546_CR18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40271-022-00581-z","volume":"15","author":"D Barthold","year":"2022","unstructured":"Barthold D, Brah AT, Graham SM, Simoni JM, Hauber B. Improvements to survey design from pilot testing a discrete-choice experiment of the preferences of persons living with HIV for long-acting antiretroviral therapies. Patient. 2022;15:513\u201320.","journal-title":"Patient"},{"key":"10546_CR19","doi-asserted-by":"crossref","first-page":"e26099","DOI":"10.1002\/jia2.26099","volume":"26","author":"SM Graham","year":"2023","unstructured":"Graham SM, et al. U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. J Int AIDS Soc. 2023;26:e26099.","journal-title":"J Int AIDS Soc"},{"key":"10546_CR20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/526786","volume":"197","author":"F Pereyra","year":"2008","unstructured":"Pereyra F, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563\u201371.","journal-title":"J Infect Dis"},{"key":"10546_CR21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381.","journal-title":"J Biomed Inf"},{"key":"10546_CR22","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"10546_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient - Patient-Centered Outcomes Res. 2015;8:373\u201384.","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"10546_CR24","unstructured":"ChoiceMetrics. Ngene 1.2. User Manual & Reference Guide. www.choice-metrics.com. 2018."},{"key":"10546_CR25","unstructured":"SurveyEngine B. SurveyEngine GmbH. (2021)."},{"key":"10546_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003620","author":"D Barthold","year":"2023","unstructured":"Barthold D, et al. Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV. AIDS Lond Engl. 2023. https:\/\/doi.org\/10.1097\/QAD.0000000000003620","journal-title":"AIDS Lond Engl"},{"key":"10546_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09540120802032627","volume":"21","author":"SC Kalichman","year":"2009","unstructured":"Kalichman SC, et al. Measuring AIDS stigmas in people living with HIV\/AIDS: the internalized AIDS-related stigma scale. AIDS Care. 2009;21:87\u201393.","journal-title":"AIDS Care"},{"key":"10546_CR28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11121-011-0201-1","volume":"14","author":"ST Lanza","year":"2013","unstructured":"Lanza ST, Rhoades BL. Latent class analysis: an alternative perspective on subgroup analysis in prevention and treatment. Prev Sci off J Soc Prev Res. 2013;14:157\u201368.","journal-title":"Prev Sci off J Soc Prev Res"},{"key":"10546_CR29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2307\/3341848","volume":"28","author":"R Andersen","year":"2003","unstructured":"Andersen R, Hagenaars JA, McCutcheon AL. Applied latent class analysis. Can J Sociol Cah Can Sociol. 2003;28:584.","journal-title":"Can J Sociol Cah Can Sociol"},{"key":"10546_CR30","unstructured":"StataCorp. Stata Statistical Software: release 14. College Station, TX: StataCorp LP; 2015."},{"key":"10546_CR31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jval.2022.01.012","volume":"25","author":"C Vass","year":"2022","unstructured":"Vass C, et al. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR Special Interest Group Report. Value Health. 2022;25:685\u201394.","journal-title":"Value Health"},{"key":"10546_CR32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJMp1109283","volume":"366","author":"MJ Barry","year":"2012","unstructured":"Barry MJ, Edgman-Levitan S. Shared decision making\u2013pinnacle of patient-centered care. N Engl J Med. 2012;366:780\u20131.","journal-title":"N Engl J Med"},{"key":"10546_CR33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/jpm12030334","volume":"12","author":"H Gelhorn","year":"2022","unstructured":"Gelhorn H, et al. Patient and physician preferences for regimen attributes for the treatment of HIV in the United States and Canada. J Pers Med. 2022;12:334.","journal-title":"J Pers Med"},{"key":"10546_CR34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.","journal-title":"BMC Health Serv Res"},{"key":"10546_CR35","doi-asserted-by":"crossref","first-page":"42365","DOI":"10.4088\/PCC.21cr03202","volume":"24","author":"MD Chochol","year":"2022","unstructured":"Chochol MD. Self-removal of implanted contraceptive during an exacerbation of paranoid Schizophrenia. Prim Care Companion CNS Disord. 2022;24:42365.","journal-title":"Prim Care Companion CNS Disord"},{"key":"10546_CR36","first-page":"159","volume":"80","author":"PR Dodds","year":"2016","unstructured":"Dodds PR, Dodds TJ, Jacoby TL. Bizarre paranoid delusions associated with an implanted surgical device. Conn Med. 2016;80:159\u201361.","journal-title":"Conn Med"},{"key":"10546_CR37","first-page":"e1371","volume":"9","author":"L Castellanos-Cosano","year":"2017","unstructured":"Castellanos-Cosano L, et al. Dental implants placement in paranoid squizofrenic patient with obsessive-compulsive disorder: a case report. J Clin Exp Dent. 2017;9:e1371\u20134.","journal-title":"J Clin Exp Dent"},{"key":"10546_CR38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.npp.1300385","volume":"29","author":"F Irani","year":"2004","unstructured":"Irani F, et al. Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology. 2004;29:960\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"10546_CR39","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/MAO.0000000000001399","volume":"38","author":"IT Herisanu","year":"2017","unstructured":"Herisanu IT, Praetorius M, Mattern M. Cochlear implant in severe impaired psychiatric patients: a case series. Otol Neurotol off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol. 2017;38:822\u20137.","journal-title":"Otol Neurotol off Publ Am Otol Soc Am Neurotol Soc Eur Acad Otol Neurotol"},{"key":"10546_CR40","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. Clin Infect Dis off Publ Infect Dis Soc Am. 2022;75:S541\u20138.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"key":"10546_CR41","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/PPA.S142643","volume":"11","author":"EF Eaton","year":"2017","unstructured":"Eaton EF, McDavid C, Banasiewicz MK, Mugavero MJ, Knight SJ. Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods. Patient Prefer Adherence. 2017;11:1585\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"10546_CR42","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2147\/PPA.S405288","volume":"17","author":"S Fifer","year":"2023","unstructured":"Fifer S, Kularatne T, Tan M, Drummond F, Rule J. Understanding treatment preferences among people living with HIV in Australia: a discrete choice experiment. Patient Prefer Adherence. 2023;17:1825\u201343.","journal-title":"Patient Prefer Adherence"},{"key":"10546_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-023-00641-y","author":"M Emmert","year":"2023","unstructured":"Emmert M, Rohrbacher S, Jahn J, Fernando K, Lauerer M. Preferences of people living with HIV for long-acting antiretroviral treatment in Germany: evidence from a discrete choice experiment. Patient - Patient-Centered Outcomes Res. 2023. https:\/\/doi.org\/10.1007\/s40271-023-00641-y","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"10546_CR44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/apc.2018.0198","volume":"33","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, et al. Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV. AIDS Patient Care STDs. 2019;33:104\u201311.","journal-title":"AIDS Patient Care STDs"},{"key":"10546_CR45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1037\/apl0000514","volume":"106","author":"AM Ryan","year":"2021","unstructured":"Ryan AM, et al. In the eye of the beholder: considering culture in assessing the social desirability of personality. J Appl Psychol. 2021;106:452\u201366.","journal-title":"J Appl Psychol"},{"key":"10546_CR46","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","volume":"77","author":"P Thoueille","year":"2021","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2021;77:290\u2013302.","journal-title":"J Antimicrob Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10546-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10546-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:32:37Z","timestamp":1739957557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10546-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10546"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10546-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The UW and Emory University both approved the study protocols and informed consent documents, and the UW served as the institutional review board (IRB) of record (STUDY00007390). All participants provided electronic informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided electronic consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BH is an employee of Pfizer, but Pfizer had no input or influence on the study. SMG has received support from Gilead and Cepheid for her research. VCM has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Merck, Gilead Sciences, and ViiV. The other authors declare that they have no conflicts of interest directly relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}